<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04847726</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-1807-166</org_study_id>
    <nct_id>NCT04847726</nct_id>
  </id_info>
  <brief_title>Contrast-enhanced Ultrasound With Perfluorobutane and Sulfur Hexafluoride for Hepatocellular Carcinoma</brief_title>
  <official_title>Comparison of Diagnostic Performance of Computed Tomography (CT), Magnetic Resonance Image (MRI), Contrast-enhanced Ultrasound (CEUS) With Perfluorobutane and Sulfur Hexafluoride for Hepatocellular Carcinoma (HCC) in High-risk Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intra-individual comparison of diagnostic performance of CT, MRI, CEUS With perfluorobutane&#xD;
      and sulfur hexafluoride for HCC in high-risk Individuals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators would compare the diagnostic performance for HCC at high-risk individuals&#xD;
      between each imaging modality.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Study participants underwent CT, MRI, contrast-enhanced ultrasound with perfluorobutane and sulfur hexafluoride. The diagnostic performance will be compared intra-individually.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic performance for HCC</measure>
    <time_frame>2 weeks</time_frame>
    <description>The rate of imaging diagnosis of HCC on CT, MRI and CEUS. (The sensitivity, specificity and accuracy)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Image feature comparison</measure>
    <time_frame>2 weeks</time_frame>
    <description>The incidence of arterial phase hyper-enhancement, washout, and capsular enhancement of hepatic lesion on CT, MRI and CEUS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Role of Kupffer phase of perfluorobutane</measure>
    <time_frame>2 weeks</time_frame>
    <description>The rate of heterogeneity on the Kupffer phase of perfluorobutane enhanced US for HCC.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>CEUS with perfluorobutane and sulfur hexafluoride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Contrast-enhanced ultrasound with perfluorobutane and sulfur hexafluoride for the hepatic lesion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>contrast enhanced ultrasound</intervention_name>
    <description>contrast enhanced ultrasound with perfluorobutane and sulfur hexafluoride</description>
    <arm_group_label>CEUS with perfluorobutane and sulfur hexafluoride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Dynamic CT</intervention_name>
    <description>Participants underwent dynamic CT for hepatic lesion</description>
    <arm_group_label>CEUS with perfluorobutane and sulfur hexafluoride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Liver MRI</intervention_name>
    <description>Participants underwent liver MRI for hepatic lesion</description>
    <arm_group_label>CEUS with perfluorobutane and sulfur hexafluoride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  high-risk for HCC (liver cirrhosis, chronic hepatitis B)&#xD;
&#xD;
          -  treatment-naive hepatic nodule (&gt;= 1cm) on preceding CT, MR or ultrasound&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  severe cardiopulmonary dysfunction&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  refusal to enroll study&#xD;
&#xD;
          -  more than 5 lesions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong Min Lee, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyo-Jin Kang, Dr.</last_name>
    <phone>82-2-2072-3107</phone>
    <email>dr.kanghj@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeong Min Lee, Dr.</last_name>
    <phone>82-2-2072-3154</phone>
    <email>jmlshy2000@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <zip>03038</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyo-Jin Kang, Dr.</last_name>
      <phone>82-2-2072-3107</phone>
      <email>dr.kanghj@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jeong Min Lee, Dr</last_name>
      <phone>82-2-2072-3154</phone>
      <email>jmlshy2000@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jeong Min Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HCC</keyword>
  <keyword>Contrast-enhanced ultrasound</keyword>
  <keyword>Perfluorobutane</keyword>
  <keyword>Sulfur hexafluoride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

